Last reviewed · How we verify
NCT04918030: SAGED
STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（STAGED）
NA trial testing Early staged PCI in STEMI in 1,586 participants. Completed in 1 February 2025.
1 February 2025
Quick facts
| Lead sponsor | Xiamen Cardiovascular Hospital, Xiamen University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 1,586 |
| Start date | 11 February 2021 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Early staged PCI
- Late staged PCI
Conditions studied
- STEMI — all drugs for STEMI →
- Multi Vessel Coronary Artery Disease — all drugs for Multi Vessel Coronary Artery Disease →
- Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
- AMI Patients With Multivessel Disease, Staged PCI — all drugs for AMI Patients With Multivessel Disease, Staged PCI →
Sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Who can join
Adults 18 to 80, any sex, with STEMI or Multi Vessel Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the difference in major adverse cardiac event (MACE) between Early staged PCI versus Late staged PCI groups among patients with ST-segment elevated myocardial infarction （STEMI and multi-vessel Disease（MVD) who underwent primary PCI using DES for culprit lesions. Background: In patients with STEMI with MVD who underwent primary PCI, complete revascularization for non-culprit lesions has proved to reduce the risk of cardiovascular death and myocardial infarction. However, the ideal timing point for staged PCI for nonculprit lesions remains uncertain.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Quantitative Flow Ratio to Predict Non-Target-Vessel Events Before Planned Staged Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Bär S, Kavaliauskaite R, Otsuka T, Ueki Y, et al · · 2024 · cited 1× · PMID 38156592 · DOI 10.1161/jaha.123.031847 -
Staged interventional strategies for acute ST-segment elevation myocardial infarction patient with multivessel disease: Rationale and design of a multicenter, randomized STAGED trial.
Chen X, Li S, Wang B, Chen G, et al · · 2026 · PMID 41539383 · DOI 10.1016/j.ahj.2026.107352 -
Complete Revascularisation Following Acute MI: A Contemporary Review.
Gonnah A, Darke N, Mullen L, Hung J, et al · · 2025 · PMID 40171022 · DOI 10.15420/icr.2024.39 -
Role of physiology in the management of multivessel disease among patients with acute coronary syndrome.
Ganzorig N, Pompei G, Jenkins K, Wang W, et al · · 2024 · PMID 39347110 · DOI 10.4244/aij-d-24-00051 -
Quantitative Flow Ratio to Predict Non-Target-Vessel Events Prior to Planned Staged PCI in ACS Patients
Bär S, Kavaliauskaite R, Otsuka T, Ueki Y, et al · · 2023 · DOI 10.1101/2023.07.24.23292979
Verify or expand the search:
- PubMed search for NCT04918030
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for STEMI
Currently open trials in the same condition.
- NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
- NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
- NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
- NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting
Other Xiamen Cardiovascular Hospital, Xiamen University trials
Trials by the same sponsor.
- NCT07055919 — Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER). · NA · recruiting
- NCT06532838 — Optimized Strategies for Malperfusion Syndrome · NA · not yet recruiting
- NCT05925335 — The China Mviv Registry · NA · unknown
- NCT05497141 — Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Sever · NA · unknown
- NCT05517356 — Prospective Study of Tailored Management Strategies for Malperfusion Syndrome · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04918030 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiamen Cardiovascular Hospital, Xiamen University
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918030.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing